You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: June 21, 2024

~ Buy the HARVONI (ledipasvir; sofosbuvir) Drug Profile, 2024 PDF Report in the Report Store ~

HARVONI Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Harvoni, and when can generic versions of Harvoni launch?

Harvoni is a drug marketed by Gilead Sciences Inc and is included in two NDAs. There are seventeen patents protecting this drug.

This drug has five hundred and fifty-five patent family members in forty-eight countries.

The generic ingredient in HARVONI is ledipasvir; sofosbuvir. There is one drug master file entry for this compound. Two suppliers are listed for this compound. Additional details are available on the ledipasvir; sofosbuvir profile page.

DrugPatentWatch® Generic Entry Outlook for Harvoni

Harvoni was eligible for patent challenges on October 10, 2018.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be September 14, 2032. This may change due to patent challenges or generic licensing.

There have been three patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

< Available with Subscription >

  Sign Up

Drug patent expirations by year for HARVONI
Drug Prices for HARVONI

See drug prices for HARVONI

Drug Sales Revenue Trends for HARVONI

See drug sales revenues for HARVONI

DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for HARVONI
Generic Entry Dates for HARVONI*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
PELLETS;ORAL
Generic Entry Dates for HARVONI*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
TABLET;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for HARVONI

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Mansoura UniversityPhase 3
Cairo UniversityPhase 2/Phase 3
University of Maryland, College ParkEarly Phase 1

See all HARVONI clinical trials

US Patents and Regulatory Information for HARVONI

HARVONI is protected by seventeen US patents and seven FDA Regulatory Exclusivities.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of HARVONI is ⤷  Sign Up.

This potential generic entry date is based on patent ⤷  Sign Up.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Patents protecting HARVONI

Combination formulation of two antiviral compounds
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Methods for treating HCV
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Nucleoside phosphoramidate prodrugs
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Antiviral compounds
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Antiviral compounds
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Nucleoside phosphoramidate prodrugs
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Nucleoside phosphoramidate prodrugs
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Nucleoside phosphoramidates
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Nucleoside phosphoramidates
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Nucleoside phosphoramidate prodrugs
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Antiviral compounds
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Antiviral compounds
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Compositions and methods for treating hepatitis C virus
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Nucleoside phosphoramidate prodrugs
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Nucleoside phosphoramidates
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Methods for treating HCV
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Antiviral compounds
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

FDA Regulatory Exclusivity protecting HARVONI

TREATMENT OF PEDIATRIC PATIENTS 3 YEARS OF AGE AND OLDER WITH CHRONIC HCV GENOTYPE 1 INFECTION WITH DECOMPENSATED CIRRHOSIS, FOR USE IN COMBINATION WITH RIBAVIRIN
Exclusivity Expiration: ⤷  Sign Up

TREATMENT OF PEDIATRIC PATIENTS BETWEEN 3 YEARS OF AGE AND 12 YEARS OF AGE OR WEIGHING 35 KG WITH CHRONIC HEPATITIS C VIRUS (HCV) GENOTYPE 1, 4, 5, OR 6 INFECTION WITHOUT CIRRHOSIS OR WITH COMPENSATED CIRRHOSIS
Exclusivity Expiration: ⤷  Sign Up

TREATMENT OF PEDIATRIC PATIENTS 3 YEARS OF AGE AND OLDER WITH CHRONIC HCV GENOTYPE 1 OR 4 INFECTION WHO ARE LIVER TRANSPLANT RECIPIENTS WITHOUT CIRRHOSIS OR WITH COMPENSATED CIRRHOSIS, FOR USE IN COMBINATION WITH RIBAVIRIN
Exclusivity Expiration: ⤷  Sign Up

FDA HAS NOT RECOGNIZED ORPHAN-DRUG EXCLUSIVITY (ODE) FOR THIS DRUG, BUT IT CONTAINS THE SAME ACTIVE MOIETY OR MOIETIES AS ANOTHER DRUG(S) THAT WAS ELIGIBLE FOR ODE, AND ALSO SHARES ODE-PROTECTED USE(S) OR INDICATION(S) WITH THAT DRUG(S).AN APPLICATION SEEKING APPROVAL FOR THE SAME ACTIVE MOIETY OR MOIETIES, INCLUDING AN ANDA THAT CITES THIS NDA AS ITS BASIS OF SUBMISSION, MAY NOT BE APPROVED FOR SUCH ODE-PROTECTED USE(S) AND INDICATION(S)
Exclusivity Expiration: ⤷  Sign Up

FDA HAS NOT RECOGNIZED ORPHAN-DRUG EXCLUSIVITY (ODE) FOR THIS DRUG, BUT IT CONTAINS THE SAME ACTIVE MOIETY OR MOIETIES AS ANOTHER DRUG(S) THAT WAS ELIGIBLE FOR ODE, AND ALSO SHARES ODE-PROTECTED USE(S) OR INDICATION(S) WITH THAT DRUG(S).AN APPLICATION SEEKING APPROVAL FOR THE SAME ACTIVE MOIETY OR MOIETIES, INCLUDING AN ANDA THAT CITES THIS NDA AS ITS BASIS OF SUBMISSION, MAY NOT BE APPROVED FOR SUCH ODE-PROTECTED USE(S) AND INDICATION(S)
Exclusivity Expiration: ⤷  Sign Up

PEDIATRIC EXCLUSIVITY
Exclusivity Expiration: ⤷  Sign Up

TREATMENT OF PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER OR WEIGHING AT LEAST 35 KG WITH CHRONIC HEPATITIS C VIRUS GENOTYPE 1, 4, 5, OR 6 INFECTION WITHOUT CIRRHOSIS OR WITH COMPENSATED CIRRHOSIS
Exclusivity Expiration: ⤷  Sign Up

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Gilead Sciences Inc HARVONI ledipasvir; sofosbuvir TABLET;ORAL 205834-001 Oct 10, 2014 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Gilead Sciences Inc HARVONI ledipasvir; sofosbuvir TABLET;ORAL 205834-002 Aug 28, 2019 RX Yes No ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Gilead Sciences Inc HARVONI ledipasvir; sofosbuvir PELLETS;ORAL 212477-002 Aug 28, 2019 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for HARVONI

When does loss-of-exclusivity occur for HARVONI?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Patent: 8580
Estimated Expiration: ⤷  Sign Up

Patent: 9578
Estimated Expiration: ⤷  Sign Up

Patent: 5131
Estimated Expiration: ⤷  Sign Up

Australia

Patent: 12308295
Estimated Expiration: ⤷  Sign Up

Patent: 12332827
Estimated Expiration: ⤷  Sign Up

Patent: 12346217
Estimated Expiration: ⤷  Sign Up

Patent: 14202687
Estimated Expiration: ⤷  Sign Up

Patent: 15202842
Estimated Expiration: ⤷  Sign Up

Patent: 16216641
Estimated Expiration: ⤷  Sign Up

Patent: 18203696
Estimated Expiration: ⤷  Sign Up

Brazil

Patent: 2014006324
Estimated Expiration: ⤷  Sign Up

Patent: 2014010295
Estimated Expiration: ⤷  Sign Up

Patent: 2014011938
Estimated Expiration: ⤷  Sign Up

Patent: 2014012739
Estimated Expiration: ⤷  Sign Up

Canada

Patent: 40242
Estimated Expiration: ⤷  Sign Up

Patent: 52867
Estimated Expiration: ⤷  Sign Up

Patent: 53495
Estimated Expiration: ⤷  Sign Up

Patent: 56529
Estimated Expiration: ⤷  Sign Up

Chile

Patent: 14000630
Estimated Expiration: ⤷  Sign Up

Patent: 14001397
Estimated Expiration: ⤷  Sign Up

Patent: 15002164
Estimated Expiration: ⤷  Sign Up

China

Patent: 4039319
Estimated Expiration: ⤷  Sign Up

Patent: 4144682
Estimated Expiration: ⤷  Sign Up

Patent: 4244945
Estimated Expiration: ⤷  Sign Up

Patent: 4244947
Estimated Expiration: ⤷  Sign Up

Patent: 5748499
Estimated Expiration: ⤷  Sign Up

Patent: 6166160
Estimated Expiration: ⤷  Sign Up

Colombia

Patent: 30366
Estimated Expiration: ⤷  Sign Up

Patent: 70603
Estimated Expiration: ⤷  Sign Up

Costa Rica

Patent: 140177
Estimated Expiration: ⤷  Sign Up

Patent: 140273
Estimated Expiration: ⤷  Sign Up

Patent: 150453
Estimated Expiration: ⤷  Sign Up

Croatia

Patent: 0180237
Estimated Expiration: ⤷  Sign Up

Patent: 0200138
Estimated Expiration: ⤷  Sign Up

Cyprus

Patent: 19896
Estimated Expiration: ⤷  Sign Up

Patent: 22718
Estimated Expiration: ⤷  Sign Up

Denmark

Patent: 09613
Estimated Expiration: ⤷  Sign Up

Patent: 50786
Estimated Expiration: ⤷  Sign Up

Ecuador

Patent: 14005678
Estimated Expiration: ⤷  Sign Up

Patent: 14013312
Estimated Expiration: ⤷  Sign Up

Patent: 15037311
Estimated Expiration: ⤷  Sign Up

Patent: 21087299
Estimated Expiration: ⤷  Sign Up

Eurasian Patent Organization

Patent: 6667
Estimated Expiration: ⤷  Sign Up

Patent: 7296
Estimated Expiration: ⤷  Sign Up

Patent: 9081
Estimated Expiration: ⤷  Sign Up

Patent: 1490588
Estimated Expiration: ⤷  Sign Up

Patent: 1490806
Estimated Expiration: ⤷  Sign Up

Patent: 1490903
Estimated Expiration: ⤷  Sign Up

European Patent Office

Patent: 09613
Estimated Expiration: ⤷  Sign Up

Patent: 76024
Estimated Expiration: ⤷  Sign Up

Patent: 85340
Estimated Expiration: ⤷  Sign Up

Patent: 50786
Estimated Expiration: ⤷  Sign Up

Patent: 50013
Estimated Expiration: ⤷  Sign Up

Patent: 77867
Estimated Expiration: ⤷  Sign Up

Germany

Patent: 2012013074
Estimated Expiration: ⤷  Sign Up

Patent: 2012013382
Estimated Expiration: ⤷  Sign Up

Hong Kong

Patent: 02268
Estimated Expiration: ⤷  Sign Up

Patent: 19869
Estimated Expiration: ⤷  Sign Up

Patent: 31378
Estimated Expiration: ⤷  Sign Up

Hungary

Patent: 36588
Estimated Expiration: ⤷  Sign Up

Patent: 47777
Estimated Expiration: ⤷  Sign Up

Israel

Patent: 1515
Estimated Expiration: ⤷  Sign Up

Patent: 2889
Estimated Expiration: ⤷  Sign Up

Patent: 3419
Estimated Expiration: ⤷  Sign Up

Japan

Patent: 99327
Estimated Expiration: ⤷  Sign Up

Patent: 73897
Estimated Expiration: ⤷  Sign Up

Patent: 23002
Estimated Expiration: ⤷  Sign Up

Patent: 20994
Estimated Expiration: ⤷  Sign Up

Patent: 14526516
Estimated Expiration: ⤷  Sign Up

Patent: 14532657
Estimated Expiration: ⤷  Sign Up

Patent: 14533733
Estimated Expiration: ⤷  Sign Up

Patent: 15508418
Estimated Expiration: ⤷  Sign Up

Patent: 16053096
Estimated Expiration: ⤷  Sign Up

Patent: 16155875
Estimated Expiration: ⤷  Sign Up

Patent: 16166251
Estimated Expiration: ⤷  Sign Up

Patent: 17057230
Estimated Expiration: ⤷  Sign Up

Lithuania

Patent: 09613
Estimated Expiration: ⤷  Sign Up

Patent: 50786
Estimated Expiration: ⤷  Sign Up

Malaysia

Patent: 2166
Estimated Expiration: ⤷  Sign Up

Patent: 7735
Estimated Expiration: ⤷  Sign Up

Mexico

Patent: 6580
Estimated Expiration: ⤷  Sign Up

Patent: 1816
Estimated Expiration: ⤷  Sign Up

Patent: 4958
Estimated Expiration: ⤷  Sign Up

Patent: 14003145
Estimated Expiration: ⤷  Sign Up

Patent: 14005955
Estimated Expiration: ⤷  Sign Up

Patent: 14006373
Estimated Expiration: ⤷  Sign Up

Moldova, Republic of

Patent: 30
Estimated Expiration: ⤷  Sign Up

Patent: 89
Estimated Expiration: ⤷  Sign Up

Patent: 95
Estimated Expiration: ⤷  Sign Up

Patent: 140035
Estimated Expiration: ⤷  Sign Up

Patent: 140058
Estimated Expiration: ⤷  Sign Up

Patent: 150080
Estimated Expiration: ⤷  Sign Up

Montenegro

Patent: 009
Estimated Expiration: ⤷  Sign Up

Morocco

Patent: 906
Estimated Expiration: ⤷  Sign Up

Patent: 150030
Estimated Expiration: ⤷  Sign Up

New Zealand

Patent: 3396
Estimated Expiration: ⤷  Sign Up

Patent: 5087
Estimated Expiration: ⤷  Sign Up

Patent: 5532
Estimated Expiration: ⤷  Sign Up

Patent: 0391
Estimated Expiration: ⤷  Sign Up

Patent: 9172
Estimated Expiration: ⤷  Sign Up

Peru

Patent: 141056
Estimated Expiration: ⤷  Sign Up

Patent: 141296
Estimated Expiration: ⤷  Sign Up

Patent: 151778
Estimated Expiration: ⤷  Sign Up

Philippines

Patent: 014501133
Estimated Expiration: ⤷  Sign Up

Patent: 015501710
Estimated Expiration: ⤷  Sign Up

Poland

Patent: 09613
Estimated Expiration: ⤷  Sign Up

Patent: 50786
Estimated Expiration: ⤷  Sign Up

Portugal

Patent: 09613
Estimated Expiration: ⤷  Sign Up

Patent: 50786
Estimated Expiration: ⤷  Sign Up

Serbia

Patent: 975
Estimated Expiration: ⤷  Sign Up

Singapore

Patent: 201602044W
Estimated Expiration: ⤷  Sign Up

Patent: 201706949V
Estimated Expiration: ⤷  Sign Up

Patent: 201400664W
Estimated Expiration: ⤷  Sign Up

Patent: 201402609R
Estimated Expiration: ⤷  Sign Up

Patent: 201506021X
Estimated Expiration: ⤷  Sign Up

Slovenia

Patent: 09613
Estimated Expiration: ⤷  Sign Up

Patent: 50786
Estimated Expiration: ⤷  Sign Up

South Africa

Patent: 1404061
Estimated Expiration: ⤷  Sign Up

South Korea

Patent: 1560994
Estimated Expiration: ⤷  Sign Up

Patent: 1962522
Estimated Expiration: ⤷  Sign Up

Patent: 1991298
Estimated Expiration: ⤷  Sign Up

Patent: 140096029
Estimated Expiration: ⤷  Sign Up

Patent: 140108645
Estimated Expiration: ⤷  Sign Up

Patent: 140119012
Estimated Expiration: ⤷  Sign Up

Patent: 160052797
Estimated Expiration: ⤷  Sign Up

Patent: 190033643
Estimated Expiration: ⤷  Sign Up

Patent: 190075142
Estimated Expiration: ⤷  Sign Up

Patent: 200060782
Estimated Expiration: ⤷  Sign Up

Spain

Patent: 59216
Estimated Expiration: ⤷  Sign Up

Patent: 71458
Estimated Expiration: ⤷  Sign Up

Patent: 17886
Estimated Expiration: ⤷  Sign Up

Taiwan

Patent: 66773
Estimated Expiration: ⤷  Sign Up

Patent: 26047
Estimated Expiration: ⤷  Sign Up

Patent: 1318627
Estimated Expiration: ⤷  Sign Up

Patent: 1325599
Estimated Expiration: ⤷  Sign Up

Patent: 1444556
Estimated Expiration: ⤷  Sign Up

Patent: 1840311
Estimated Expiration: ⤷  Sign Up

Patent: 2042808
Estimated Expiration: ⤷  Sign Up

Turkey

Patent: 1802537
Estimated Expiration: ⤷  Sign Up

Ukraine

Patent: 4097
Estimated Expiration: ⤷  Sign Up

Patent: 6087
Estimated Expiration: ⤷  Sign Up

Patent: 8256
Estimated Expiration: ⤷  Sign Up

Uruguay

Patent: 420
Estimated Expiration: ⤷  Sign Up

Patent: 474
Estimated Expiration: ⤷  Sign Up

Patent: 299
Estimated Expiration: ⤷  Sign Up

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering HARVONI around the world.

Country Patent Number Title Estimated Expiration
European Patent Office 2857394 Composés antiviraux (Antiviral compounds) ⤷  Sign Up
Canada 2915187 ESTER DE N-[(2'R)-2'-DESOXY-2'-FLUORO-2'-METHYL-P-PHENYL-5'-URIDYLYL]-L-ALANINE 1-METHYLETHYLE ET SON PROCEDE DE PRODUCTION (N-[(2'R)-2'-DEOXY-2'-FLUORO-2'-METHYL-P-PHENYL-5'-URIDYLYL]-L-ALANINE 1-METHYLETHYL ESTER AND PROCESS FOR ITS PRODUCTION) ⤷  Sign Up
Portugal 2752422 ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for HARVONI

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2430014 PA2016002,C2430014 Lithuania ⤷  Sign Up PRODUCT NAME: LEDIPASVIRAS; REGISTRATION NO/DATE: EU/1/14/958(001-002) 20141117
2430014 PA2016002 Lithuania ⤷  Sign Up PRODUCT NAME: LEDIPASVIRAS; REGISTRATION NO/DATE: EU/1/14/958(001-002) 20141118
2203462 C201430078 Spain ⤷  Sign Up PRODUCT NAME: SOFOSBUVIR; NATIONAL AUTHORISATION NUMBER: EU/1/13/894; DATE OF AUTHORISATION: 20140116; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/13/894; DATE OF FIRST AUTHORISATION IN EEA: 20140116
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.